From Wikipedia, the free encyclopedia
Jump to: navigation, search
Combination of
Artesunate Antimalarial
Amodiaquine Antimalarial
Clinical data
Trade names Coarsucam
  • US: C (Risk not ruled out)
CAS Number 944945-14-6 N
ATC code P01BF03 (WHO)
ChemSpider none
 NYesY (what is this?)  (verify)

Artesunate/amodiaquine (trade name Coarsucam) is a fixed-dose artemisinin-based combination therapy (ACT) indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria.

Early clinical trials showed that a once-a-day dosage was effective.[1] It was subsequently clinically shown to be equally effective as artemether/lumefantrine ("Coartem"),[2] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.

It was launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis.[3] The drug is patent free.[4]

It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.[5]


  1. ^ Ndiaye, Jean; Randrianarivelojosia, Milijaona; Sagara, Issaka; Brasseur, Philippe; Ndiaye, Ibrahima; Faye, Babacar; Randrianasolo, Laurence; Ratsimbasoa, Arsène; Forlemu, Doris; Moor, Vicky; Traore, Aminata; Dicko, Yahia; Dara, Niawanlou; Lameyre, Valérie; Diallo, Mouctar; Djimde, Abdoulaye; Same-Ekobo, Albert; Gaye, Oumar (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. 8: 125. doi:10.1186/1475-2875-8-125. PMC 2698916free to read. PMID 19505304. Retrieved 18 January 2013. 
  2. ^ Nidiaye, Jean-Louis A; Faye, Babacar; Gueye, Ali; Tine, Roger; Ndiaye, Daouda; Tchania, Corinne; Ndiaye, Ibrahima; Barry, Aichatou; Cissé, Badara; Lameyre, Valérie; Gaye, Oumar (2011). "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. 10: 237. doi:10.1186/1475-2875-10-237. PMC 3171378free to read. PMID 21838909. Retrieved 18 January 2013. 
  3. ^ "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available".  080218
  4. ^ "ASAQ - The $1 Future of Malaria Treatment « GlobaLab".  080218
  5. ^ "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015. 

External links[edit]